Effects of atorvastatin on higher functions
This study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions. In this before and after comparison study with controls, group one included 55 subjects aged > or =40 years requiring statins for cardiovascular indications who were started on atorvastatin (...
Saved in:
Published in | European journal of clinical pharmacology Vol. 62; no. 4; pp. 259 - 265 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Heidelberg
Springer
01.04.2006
Berlin Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions.
In this before and after comparison study with controls, group one included 55 subjects aged > or =40 years requiring statins for cardiovascular indications who were started on atorvastatin (10 mg/day). Group two assigned to receive placebo were men and women chosen from the same geographical area and matched for age, sex, education and presence of hypertension and diabetes mellitus. Assessment was done with the Mini-Mental State Examination, Digit Span, Picture Test (average and delayed), Trail Making Test, Controlled Oral Word Association Test, Digit Symbol Substitution Test and Auditory Vigilance and Digit Vigilance Test at baseline and after 6 months. Changes between baseline and 6 months in the above parameters of mental function were compared using suitable statistical tests in the atorvastatin and placebo groups. To limit experiment-wise error, performance scores were grouped into five cognitive domains, which were labeled as attention, psychomotor speed, mental flexibility, working memory and memory retrieval. Summary effect sizes were estimated as z-scores.
Both subjects on atorvastatin and placebo showed improvement in the majority of scales consistent with a learning effect on test performance. However, subjects treated with atorvastatin scored significantly over the placebo group in all domains, i.e. tests of attention [z-score=0.54, 95% confidence interval (CI): 0.38-0.64, p=0.001], psychomotor speed (z-score=0.28, 95% CI: O.09-0.47, p<0.001), mental flexibility (z-score=0.27, 95% CI: 0.22-0.32, p=0.01), working memory (z-score=1.22, 95% CI: 0.93-1.50, p<0.001) and memory retrieval (z-score=0.59, 95% CI: 0.36-0.82, p<0.05).
The present study concludes that there are significant beneficial effects of atorvastatin in a dose of 10 mg/day for a period of 6 months on higher functions as measured by the above standard neurocognitive tests. |
---|---|
AbstractList | OBJECTIVEThis study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions.METHODSIn this before and after comparison study with controls, group one included 55 subjects aged > or =40 years requiring statins for cardiovascular indications who were started on atorvastatin (10 mg/day). Group two assigned to receive placebo were men and women chosen from the same geographical area and matched for age, sex, education and presence of hypertension and diabetes mellitus. Assessment was done with the Mini-Mental State Examination, Digit Span, Picture Test (average and delayed), Trail Making Test, Controlled Oral Word Association Test, Digit Symbol Substitution Test and Auditory Vigilance and Digit Vigilance Test at baseline and after 6 months. Changes between baseline and 6 months in the above parameters of mental function were compared using suitable statistical tests in the atorvastatin and placebo groups. To limit experiment-wise error, performance scores were grouped into five cognitive domains, which were labeled as attention, psychomotor speed, mental flexibility, working memory and memory retrieval. Summary effect sizes were estimated as z-scores.RESULTSBoth subjects on atorvastatin and placebo showed improvement in the majority of scales consistent with a learning effect on test performance. However, subjects treated with atorvastatin scored significantly over the placebo group in all domains, i.e. tests of attention [z-score=0.54, 95% confidence interval (CI): 0.38-0.64, p=0.001], psychomotor speed (z-score=0.28, 95% CI: O.09-0.47, p<0.001), mental flexibility (z-score=0.27, 95% CI: 0.22-0.32, p=0.01), working memory (z-score=1.22, 95% CI: 0.93-1.50, p<0.001) and memory retrieval (z-score=0.59, 95% CI: 0.36-0.82, p<0.05).CONCLUSIONThe present study concludes that there are significant beneficial effects of atorvastatin in a dose of 10 mg/day for a period of 6 months on higher functions as measured by the above standard neurocognitive tests. This study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions. In this before and after comparison study with controls, group one included 55 subjects aged ≥40 years requiring statins for cardiovascular indications who were started on atorvastatin (10 mg/day). Group two assigned to receive placebo were men and women chosen from the same geographical area and matched for age, sex, education and presence of hypertension and diabetes mellitus. Assessment was done with the Mini-Mental State Examination, Digit Span, Picture Test (average and delayed), Trail Making Test, Controlled Oral Word Association Test, Digit Symbol Substitution Test and Auditory Vigilance and Digit Vigilance Test at baseline and after 6 months. Changes between baseline and 6 months in the above parameters of mental function were compared using suitable statistical tests in the atorvastatin and placebo groups. To limit experiment-wise error, performance scores were grouped into five cognitive domains, which were labeled as attention, psychomotor speed, mental flexibility, working memory and memory retrieval. Summary effect sizes were estimated as z-scores. Both subjects on atorvastatin and placebo showed improvement in the majority of scales consistent with a learning effect on test performance. However, subjects treated with atorvastatin scored significantly over the placebo group in all domains, i.e. tests of attention [z-score=0.54, 95% confidence interval (CI): 0.38-0.64, p=0.001], psychomotor speed (z-score=0.28, 95% CI: O.09-0.47, p<0.001), mental flexibility (z-score=0.27, 95% CI: 0.22-0.32, p=0.01), working memory (z-score=1.22, 95% CI: 0.93-1.50, p<0.001) and memory retrieval (z-score=0.59, 95% CI: 0.36-0.82, p<0.05). The present study concludes that there are significant beneficial effects of atorvastatin in a dose of 10 mg/day for a period of 6 months on higher functions as measured by the above standard neurocognitive tests. [PUBLICATION ABSTRACT] This study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions. In this before and after comparison study with controls, group one included 55 subjects aged > or =40 years requiring statins for cardiovascular indications who were started on atorvastatin (10 mg/day). Group two assigned to receive placebo were men and women chosen from the same geographical area and matched for age, sex, education and presence of hypertension and diabetes mellitus. Assessment was done with the Mini-Mental State Examination, Digit Span, Picture Test (average and delayed), Trail Making Test, Controlled Oral Word Association Test, Digit Symbol Substitution Test and Auditory Vigilance and Digit Vigilance Test at baseline and after 6 months. Changes between baseline and 6 months in the above parameters of mental function were compared using suitable statistical tests in the atorvastatin and placebo groups. To limit experiment-wise error, performance scores were grouped into five cognitive domains, which were labeled as attention, psychomotor speed, mental flexibility, working memory and memory retrieval. Summary effect sizes were estimated as z-scores. Both subjects on atorvastatin and placebo showed improvement in the majority of scales consistent with a learning effect on test performance. However, subjects treated with atorvastatin scored significantly over the placebo group in all domains, i.e. tests of attention [z-score=0.54, 95% confidence interval (CI): 0.38-0.64, p=0.001], psychomotor speed (z-score=0.28, 95% CI: O.09-0.47, p<0.001), mental flexibility (z-score=0.27, 95% CI: 0.22-0.32, p=0.01), working memory (z-score=1.22, 95% CI: 0.93-1.50, p<0.001) and memory retrieval (z-score=0.59, 95% CI: 0.36-0.82, p<0.05). The present study concludes that there are significant beneficial effects of atorvastatin in a dose of 10 mg/day for a period of 6 months on higher functions as measured by the above standard neurocognitive tests. |
Author | PANCHAL, N. V KULKARNI, P. M BAHETI, N. N PARALE, G. P |
Author_xml | – sequence: 1 givenname: G. P surname: PARALE fullname: PARALE, G. P organization: Department of Medicine, Dr. V.M. Medical College Solapur, Maharashtra, India – sequence: 2 givenname: N. N surname: BAHETI fullname: BAHETI, N. N organization: Department of Medicine, Dr. V.M. Medical College Solapur, Maharashtra, India – sequence: 3 givenname: P. M surname: KULKARNI fullname: KULKARNI, P. M organization: Department of Medicine, Dr. V.M. Medical College Solapur, Maharashtra, India – sequence: 4 givenname: N. V surname: PANCHAL fullname: PANCHAL, N. V organization: Clinical Pharmacist, Spandan Cardiac Diagnostic Centre, Solapur, Maharashtra, India |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17712711$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16489473$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkF1LwzAUhoMo7kN_gDdSBL2R6jlJmrSXMuYHDLzZfUi7xHV0yUxawf16O1YYeHF4b5735fBMyLnzzhByg_CEAPI5AlCapwBZf5Kl-zMyRs5oisDxnIwBGKaikDAikxg3AJgVwC7JCAXPCy7ZmDzOrTVVGxNvE9368KNjq9vaJd4l6_prbUJiO1e1tXfxilxY3URzPeSULF_ny9l7uvh8-5i9LNKKU9qm0nDQhTG8ACxzLrMK0fZRAqfWQMlXuc0LazOmAXhhC6qN1SIrmaZCrNiUPBxnd8F_dya2alvHyjSNdsZ3UQmZMyEg68G7f-DGd8H1rymKnOcilwcIj1AVfIzBWLUL9VaHX4WgDhbV0aLqLaqDRbXvO7fDcFduzerUGLT1wP0A6FjpxgbtqjqeOCmRSkT2B3WAelw |
CitedBy_id | crossref_primary_10_4103_jiag_jiag_34_21 crossref_primary_10_1248_jhs_55_215 crossref_primary_10_1345_aph_1Q620 crossref_primary_10_1111_j_1526_4610_2008_01083_x crossref_primary_10_1007_s40263_013_0135_1 crossref_primary_10_1016_j_jacl_2014_02_013 crossref_primary_10_1586_ern_09_25 crossref_primary_10_1007_s00213_011_2245_0 crossref_primary_10_1111_j_1751_7893_2008_00102_x crossref_primary_10_1016_j_ccl_2015_02_008 crossref_primary_10_1016_j_exger_2008_05_004 crossref_primary_10_1017_S1041610214001197 crossref_primary_10_1016_S0034_7450_14_60037_8 crossref_primary_10_2337_dcS15_3022 crossref_primary_10_1007_s40264_014_0163_x crossref_primary_10_1016_j_pbb_2007_03_010 crossref_primary_10_1186_s13063_016_1370_9 crossref_primary_10_2165_00002512_200926030_00003 crossref_primary_10_1016_j_neubiorev_2010_04_010 crossref_primary_10_1007_s40263_014_0147_5 crossref_primary_10_1016_j_jacc_2012_07_007 crossref_primary_10_1097_WAD_0b013e3181a80242 crossref_primary_10_1186_1745_6215_15_202 crossref_primary_10_1016_j_ecl_2015_09_007 crossref_primary_10_2139_ssrn_4797552 crossref_primary_10_1007_s11883_012_0301_9 crossref_primary_10_1007_s40266_015_0240_6 crossref_primary_10_3346_jkms_2012_27_4_459 crossref_primary_10_3346_jkms_2012_27_4_458 crossref_primary_10_1016_j_mayocp_2013_07_013 crossref_primary_10_1016_j_yebeh_2010_07_024 crossref_primary_10_1016_j_neurobiolaging_2007_09_012 |
Cites_doi | 10.1111/j.1365-2125.1995.tb04458.x 10.1001/archinte.164.2.153 10.1038/sj.bjp.0704070 10.1093/clinchem/18.6.499 10.2165/00003495-200363090-00004 10.1016/S0140-6736(02)11600-X 10.1001/archneur.59.3.378 10.1016/S0002-9343(00)00353-3 10.1073/pnas.081620098 10.2165/00003495-200161020-00005 10.1592/phco.23.15.1663.31953 10.2337/diabetes.52.9.2396 10.1097/00041433-200104000-00003 10.1073/pnas.081612998 10.5694/j.1326-5377.1990.tb126217.x 10.1016/0022-3956(75)90026-6 10.1136/jnnp.73.4.385 10.2165/00003495-200262150-00002 10.1097/00006842-199501000-00008 10.1111/j.1532-5415.1997.tb02931.x 10.1001/archneur.59.2.223 10.1002/ana.10292 10.1111/j.1365-2125.1994.tb04268.x 10.1037/0278-6133.15.2.102 10.1136/bmj.309.6952.421 10.1093/gerona/57.7.M414 10.1001/archneur.57.10.1439 10.1016/0022-2828(91)90091-Y 10.1016/S0140-6736(00)03155-X 10.1592/phco.23.7.871.32720 10.1592/phco.21.7.767.34577 10.7326/0003-4819-128-6-199803150-00009 |
ContentType | Journal Article |
Copyright | 2006 INIST-CNRS Springer-Verlag 2006 |
Copyright_xml | – notice: 2006 INIST-CNRS – notice: Springer-Verlag 2006 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7TK 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1007/s00228-005-0073-z |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database (ProQuest) Neurosciences Abstracts Virology and AIDS Abstracts ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection Neurosciences Abstracts ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Virology and AIDS Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-1041 |
EndPage | 265 |
ExternalDocumentID | 1017551671 10_1007_s00228_005_0073_z 16489473 17712711 |
Genre | Controlled Clinical Trial Journal Article Comparative Study |
GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 08R 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 476 53G 5QI 5RE 5VS 67N 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8FW 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYOK AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFO ACGFS ACHSB ACHVE ACHXU ACIGE ACIHN ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACREN ACTTH ACVWB ACWMK ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADMDM ADOAH ADOXG ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEAQA AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFDYV AFEXP AFFNX AFGCZ AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKALU AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG AOSHJ ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECT EIHBH EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMJXF HQYDN HRMNR HZ~ I09 IHE IJ- IKXTQ IMOTQ IQODW ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 WOW Y6R YLTOR Z45 Z7U Z7V Z7W Z81 Z82 Z83 Z87 Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AACDK AAEOY AAJBT AAQLM AASML ABAKF ABJNI ACAOD ACDTI ACZOJ ADOJX AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU ALIPV CGR CUY CVF ECM EIF HMCUK HVGLF NPM AAYXX CITATION 7TK 7U9 7XB 8FK H94 K9. PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c422t-7e40a9ee4901b8475c11f475b042fe0b4d8f89ff53a0049f92aefa65b3a266d3 |
IEDL.DBID | 7X7 |
ISSN | 0031-6970 |
IngestDate | Sun Sep 29 07:35:00 EDT 2024 Fri Sep 13 03:34:21 EDT 2024 Thu Sep 12 19:07:10 EDT 2024 Sat Sep 28 07:47:25 EDT 2024 Sun Oct 22 16:04:24 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human Enzyme Memory MMSE Enzyme inhibitor Atorvastatin Hydroxymethylglutaryl-CoA reductase Statin derivative Oxidoreductases Neurocognitive tests Statins Antilipemic agent |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c422t-7e40a9ee4901b8475c11f475b042fe0b4d8f89ff53a0049f92aefa65b3a266d3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 16489473 |
PQID | 214486875 |
PQPubID | 47171 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_67836605 proquest_journals_214486875 crossref_primary_10_1007_s00228_005_0073_z pubmed_primary_16489473 pascalfrancis_primary_17712711 |
PublicationCentury | 2000 |
PublicationDate | 2006-04-01 |
PublicationDateYYYYMMDD | 2006-04-01 |
PublicationDate_xml | – month: 04 year: 2006 text: 2006-04-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Heidelberg Berlin |
PublicationPlace_xml | – name: Berlin – name: Heidelberg – name: Germany |
PublicationTitle | European journal of clinical pharmacology |
PublicationTitleAlternate | Eur J Clin Pharmacol |
PublicationYear | 2006 |
Publisher | Springer Springer Nature B.V |
Publisher_xml | – name: Springer – name: Springer Nature B.V |
References | 11890840 - Arch Neurol. 2002 Mar;59(3):378-84 12084801 - J Gerontol A Biol Sci Med Sci. 2002 Jul;57(7):M414-8 2233483 - Med J Aust. 1990 Nov 5;153(9):562-3 9499332 - Ann Intern Med. 1998 Mar 15;128(6):478-87 8681917 - Health Psychol. 1996 Mar;15(2):102-9 12457784 - Lancet. 2002 Nov 23;360(9346):1623-30 11030795 - Arch Neurol. 2000 Oct;57(10):1439-43 11264981 - Curr Opin Lipidol. 2001 Apr;12(2):105-12 7732160 - Psychosom Med. 1995 Jan-Feb;57(1):50-3 11296263 - Proc Natl Acad Sci U S A. 2001 May 8;98(10):5856-61 11309494 - Proc Natl Acad Sci U S A. 2001 May 8;98 (10 ):5815-20 10806282 - Am J Med. 2000 May;108(7):538-46 12381218 - Drugs. 2002;62(15):2185-91 9361657 - J Am Geriatr Soc. 1997 Nov;45(11):1324-30 1202204 - J Psychiatr Res. 1975 Nov;12(3):189-98 12235304 - J Neurol Neurosurg Psychiatry. 2002 Oct;73(4):385-9 11375257 - Br J Pharmacol. 2001 Jun;133(3):406-12 11401190 - Pharmacotherapy. 2001 Jun;21(6):767-9 4337382 - Clin Chem. 1972 Jun;18(6):499-502 12885101 - Pharmacotherapy. 2003 Jul;23(7):871-80 11089820 - Lancet. 2000 Nov 11;356(9242):1627-31 12678574 - Drugs. 2003;63(9):893-911 14744838 - Arch Intern Med. 2004 Jan 26;164(2):153-62 12474023 - J Nutr Health Aging. 2002;6(5):324-31 11843693 - Arch Neurol. 2002 Feb;59(2):223-7 12941781 - Diabetes. 2003 Sep;52(9):2396-402 7920112 - BMJ. 1994 Aug 13;309(6952):421-2 7619678 - Br J Clin Pharmacol. 1995 Mar;39(3):333-6 14695047 - Pharmacotherapy. 2003 Dec;23(12):1663-7 8198930 - Br J Clin Pharmacol. 1994 Mar;37(3):231-6 12205648 - Ann Neurol. 2002 Sep;52(3):346-50 11270938 - Drugs. 2001;61(2):197-206 1803025 - J Mol Cell Cardiol. 1991 Nov;23(11):1339-42 I Hajjar (73_CR14) 2002; 57 DL Sparks (73_CR36) 2002; 6 PJ Houx (73_CR16) 2002; 73 U Laufs (73_CR21) 2002; 106 JL Raggat (73_CR28) 2002; 62 H Jick (73_CR17) 2000; 356 73_CR31 A Beatrice (73_CR1) 2004; 164 B Wolozin (73_CR42) 2000; 57 A Orsi (73_CR27) 2001; 21 H Wehr (73_CR41) 1996; 15 R Krysiak (73_CR20) 2003; 63 MF Muldoon (73_CR25) 2000 L Cattin (73_CR3) 1997; 45 MF Folstein (73_CR10) 1975; 12 O Spreen (73_CR37) 1991 K Fassbender (73_CR9) 2001; 98 K Yaffe (73_CR43) 2002; 59 ED Grobbee (73_CR13) 2003; 63 A Ryman (73_CR33) 1994; 309 SR Waldstein (73_CR32) 1996; 15 M Simons (73_CR35) 2002; 52 MF Muldoon (73_CR24) 2000; 108 D Wechsler (73_CR40) 1997 WT Friedewald (73_CR11) 1972; 18 TJ Stalker (73_CR38) 2001; 133 JM Dietschy (73_CR7) 2001; 12 JD England (73_CR8) 1999; 153 BA Golomb (73_CR12) 1998; 128 RM Reitan (73_CR29) 1993 E Kojro (73_CR19) 2001; 98 MJM Dales (73_CR6) 2000; 1 RF Lewis (73_CR22) 1979 LR Wagstaff (73_CR39) 2003; 23 DS King (73_CR18) 2003; 23 N Cutler (73_CR4) 1995; 39 D Benton (73_CR2) 1995; 57 J Shepherd (73_CR34) 2002; 360 RP Mason (73_CR23) 1991; 23 MA Cotter (73_CR26) 2003; 52 K Rockwood (73_CR30) 2002; 59 MH Davidson (73_CR5) 2001; 61 RWS Harrison (73_CR15) 1994; 37 |
References_xml | – volume: 39 start-page: 333 year: 1995 ident: 73_CR4 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1995.tb04458.x contributor: fullname: N Cutler – volume: 164 start-page: 153 year: 2004 ident: 73_CR1 publication-title: Arch Int Med doi: 10.1001/archinte.164.2.153 contributor: fullname: A Beatrice – volume: 6 start-page: 323 year: 2002 ident: 73_CR36 publication-title: J Nutr Health Aging contributor: fullname: DL Sparks – volume: 133 start-page: 406 issue: 3 year: 2001 ident: 73_CR38 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0704070 contributor: fullname: TJ Stalker – volume: 18 start-page: 499 issue: 6 year: 1972 ident: 73_CR11 publication-title: Clin Chem doi: 10.1093/clinchem/18.6.499 contributor: fullname: WT Friedewald – volume: 63 start-page: 893 issue: 9 year: 2003 ident: 73_CR20 publication-title: Drugs doi: 10.2165/00003495-200363090-00004 contributor: fullname: R Krysiak – volume: 360 start-page: 1623 year: 2002 ident: 73_CR34 publication-title: Lancet doi: 10.1016/S0140-6736(02)11600-X contributor: fullname: J Shepherd – volume: 15 start-page: 267 year: 1996 ident: 73_CR41 publication-title: Age Ageing contributor: fullname: H Wehr – volume: 59 start-page: 378 issue: 3 year: 2002 ident: 73_CR43 publication-title: Arch Neurol doi: 10.1001/archneur.59.3.378 contributor: fullname: K Yaffe – volume: 108 start-page: 538 year: 2000 ident: 73_CR24 publication-title: Am J Med doi: 10.1016/S0002-9343(00)00353-3 contributor: fullname: MF Muldoon – volume: 98 start-page: 5856 year: 2001 ident: 73_CR9 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.081620098 contributor: fullname: K Fassbender – volume-title: Manual for repeatable cognitive perceptual motor battery year: 1979 ident: 73_CR22 contributor: fullname: RF Lewis – volume: 61 start-page: 197 year: 2001 ident: 73_CR5 publication-title: Drugs doi: 10.2165/00003495-200161020-00005 contributor: fullname: MH Davidson – ident: 73_CR31 – volume: 63 start-page: 893 issue: 9 year: 2003 ident: 73_CR13 publication-title: Drugs doi: 10.2165/00003495-200363090-00004 contributor: fullname: ED Grobbee – volume-title: A compendium of neuropsychological tests. Administration, norms, and commentary year: 1991 ident: 73_CR37 contributor: fullname: O Spreen – volume: 23 start-page: 1663 issue: 12 year: 2003 ident: 73_CR18 publication-title: Pharmacotherapy doi: 10.1592/phco.23.15.1663.31953 contributor: fullname: DS King – volume: 52 start-page: 2396 issue: 9 year: 2003 ident: 73_CR26 publication-title: Diabetes doi: 10.2337/diabetes.52.9.2396 contributor: fullname: MA Cotter – volume: 12 start-page: 105 year: 2001 ident: 73_CR7 publication-title: Curr Opin Lipidol doi: 10.1097/00041433-200104000-00003 contributor: fullname: JM Dietschy – volume: 98 start-page: 5815 year: 2001 ident: 73_CR19 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.081612998 contributor: fullname: E Kojro – volume: 1 start-page: 55 year: 2000 ident: 73_CR6 publication-title: Intern Med News contributor: fullname: MJM Dales – volume: 153 start-page: 562 year: 1999 ident: 73_CR8 publication-title: Med J Aust doi: 10.5694/j.1326-5377.1990.tb126217.x contributor: fullname: JD England – volume: 12 start-page: 189 year: 1975 ident: 73_CR10 publication-title: J Psychiatr Res doi: 10.1016/0022-3956(75)90026-6 contributor: fullname: MF Folstein – volume: 73 start-page: 385 issue: 4 year: 2002 ident: 73_CR16 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.73.4.385 contributor: fullname: PJ Houx – volume: 62 start-page: 2185 issue: 15 year: 2002 ident: 73_CR28 publication-title: Drugs doi: 10.2165/00003495-200262150-00002 contributor: fullname: JL Raggat – volume-title: Wechsler Adult Intelligence Scale year: 1997 ident: 73_CR40 contributor: fullname: D Wechsler – volume: 57 start-page: 50 year: 1995 ident: 73_CR2 publication-title: Psychosom Med doi: 10.1097/00006842-199501000-00008 contributor: fullname: D Benton – volume: 106 start-page: I272 issue: 19 suppl year: 2002 ident: 73_CR21 publication-title: Circulation contributor: fullname: U Laufs – volume: 45 start-page: 1324 year: 1997 ident: 73_CR3 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.1997.tb02931.x contributor: fullname: L Cattin – volume: 59 start-page: 223 issue: 2 year: 2002 ident: 73_CR30 publication-title: Arch Neurol doi: 10.1001/archneur.59.2.223 contributor: fullname: K Rockwood – volume: 52 start-page: 346 year: 2002 ident: 73_CR35 publication-title: Ann Neurol doi: 10.1002/ana.10292 contributor: fullname: M Simons – volume: 37 start-page: 231 issue: 3 year: 1994 ident: 73_CR15 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1994.tb04268.x contributor: fullname: RWS Harrison – volume: 15 start-page: 102 year: 1996 ident: 73_CR32 publication-title: Health Psychol doi: 10.1037/0278-6133.15.2.102 contributor: fullname: SR Waldstein – volume: 309 start-page: 421 year: 1994 ident: 73_CR33 publication-title: BMJ doi: 10.1136/bmj.309.6952.421 contributor: fullname: A Ryman – volume: 57 start-page: M414 issue: 7 year: 2002 ident: 73_CR14 publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/57.7.M414 contributor: fullname: I Hajjar – volume: 57 start-page: 1439 year: 2000 ident: 73_CR42 publication-title: Arch Neurol doi: 10.1001/archneur.57.10.1439 contributor: fullname: B Wolozin – volume-title: The Halstead-Reitan neuropsychological test battery. Theory and clinical interpretation year: 1993 ident: 73_CR29 contributor: fullname: RM Reitan – volume: 23 start-page: 1339 year: 1991 ident: 73_CR23 publication-title: J Mol Cell Cardiol doi: 10.1016/0022-2828(91)90091-Y contributor: fullname: RP Mason – volume: 356 start-page: 1627 issue: 9242 year: 2000 ident: 73_CR17 publication-title: Lancet doi: 10.1016/S0140-6736(00)03155-X contributor: fullname: H Jick – volume: 23 start-page: 871 issue: 7 year: 2003 ident: 73_CR39 publication-title: Pharmacotherapy doi: 10.1592/phco.23.7.871.32720 contributor: fullname: LR Wagstaff – volume: 21 start-page: 767 issue: 6 year: 2001 ident: 73_CR27 publication-title: Pharmacotherapy doi: 10.1592/phco.21.7.767.34577 contributor: fullname: A Orsi – volume: 128 start-page: 478 year: 1998 ident: 73_CR12 publication-title: Ann Intern Med doi: 10.7326/0003-4819-128-6-199803150-00009 contributor: fullname: BA Golomb – volume-title: Neuropsychology of cardiovascular disease year: 2000 ident: 73_CR25 contributor: fullname: MF Muldoon |
SSID | ssj0015903 |
Score | 2.040182 |
Snippet | This study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions.
In this before and after comparison study with... This study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions. In this before and after comparison study with... OBJECTIVEThis study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions.METHODSIn this before and after comparison... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 259 |
SubjectTerms | Atorvastatin Calcium Biological and medical sciences Cardiovascular Diseases - complications Cardiovascular Diseases - drug therapy Cognition - drug effects Female Heptanoic Acids - administration & dosage Heptanoic Acids - pharmacology Humans Intelligence Tests Male Medical sciences Mental Processes - drug effects Middle Aged Pharmacology. Drug treatments Pyrroles - administration & dosage Pyrroles - pharmacology Treatment Outcome |
Title | Effects of atorvastatin on higher functions |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16489473 https://www.proquest.com/docview/214486875/abstract/ https://search.proquest.com/docview/67836605 |
Volume | 62 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Na9wwEB3ycSmE0jRt46bZ6hByaCLWlmXLPpVsyTYUuixlA3szkizRXuxNvSkkv74zttdLDslJB2MdnkZ6M9LMG4CzMsksxg2Sl2g-XAqB56DRGS9Tj_SSeisMFSf_nKU3t_LHMlnuwPdNLQylVW7OxPagLmtLd-RjkvbKUvSux9rQJYBdj7-u7ji1j6Jn1r6Xxi7sRwK9CjRstRwiL6TssFffjXiaq-F5M2zVRAWJNFMOG5o7f3xCUAcr3SBWvmty8bwX2rLR9A287t1IdtWt-yHsuOotnM87HeqHS7bYllU1l-yczbcK1Q9HcNFpFjes9oyC7n-a6or-VKyu2O828YMR37Um-Q4W0-vFtxved03gFqFec-VkqHPnJDK9Qe5JbBR5HAxuT-9CI8vMZ7n3SawpPPC50M7rNDGxRrIu4_ewV9WVOwamdBKa3IVKKyttLk0pkjJzeWZiZYS3AXzZIFWsOm2MYlBBbmEtENaCYC0eAxg9wXL7h1KRUFEUwMkG3KLfR00xrHoAn4evuAHoVUNXrr5vipTqUDAoC-BDtyLbmVOZ5VLFH1-c-QReddcqlI3zCfbWf-_dKToaazNqjWgE-1fTyWSG4-R6Nv_1H-LQ01w |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,31755,33779,33780,43345,43840,74102,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV07T8MwED7xGEBCiDfhVQ-IAbDIw4mTCSEEKlAQQ5G6WXZiC5akkBap_fWckzQVA0wZrHj4fPZ3Z999B3CahXGKcQOjGZoPZb6P56CSMc0ig_QSmdRXtjj5-SXqvrHHQThocnPKJq1ydiZWB3VWpPaO_MpKe8URetfXw09qm0bZx9Wmg8YiLLMgYDajjw_aeAuJ2m00dz0aJbx91HQrDVHfSjPbzDU0cjr9RUtrQ1kiQqZubfG371lx0P0GrDfOI7mpV3sTFnS-BWevtfr05JL058VU5SU5I69zXerJNlzUSsUlKQyxofa3tNVEHzkpcvJepXsQy3KVIe5A__6uf9ulTa8EmiLAI8o1c2WiNUN-V8g4Yep5Bj8KN6XRrmJZbOLEmDCQNigwiS-1kVGoAokUnQW7sJQXud4HwmXoqkS7XPKUpQlTmR9msU5iFXDlm9SB8xlSYlgrYohW-7iCVSCswsIqpg6c_MJy_gfnns89z4HDGbii2T2laNfagU47imZv3zJkrotxKSJbfYKhmAN79YrMZ45YnDAeHPw7cwdWuv3nnug9vDwdwmp9sWLzcY5gafQ11sfoaozUSWVQP3Kdz3k |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB6VVqqQKkR5hkLrQ9VDqdU8_IhPCNquCpTVCi1Sb5ad2IJLsiVbpPbXM068WfUApxyi-PB57G8mM_MNwGHNywrjBkZrNB_K8hzvQWtKWguP9CJ8ldvQnPxtKi5_sC_X_DpKCnWxrHJ1J_YXdd1W4R_5aZD2KgV616c-VkXMzicfFjc0DJAKidY4TeMRbEkmOBr41qeL6ez7mFLgKo0KvBkVSo4pzrRXFM2DUHOoY0OTp_cPSGpnYTrEyw-DLv7tifaMNHkKT6IrST4Oe78LG655BkezQYv67oTM161V3Qk5IrO1SvXdc3g_6BZ3pPUkBN5_TOgt-tWQtiE_--IPEjivN8sXMJ9czM8uaZycQCuEe0mlY6lRzjFke4v8w6ss8_iweES9Sy2rS18q73lhQojgVW6cN4LbwiBh18VL2Gzaxr0GIg1PrXKpNLJilWK2znldOlXaQtrcVwkcr5DSi0EfQ49KyD2sGmHVAVZ9n8D-AyzXX0iZ5TLLEthbgavjWer0uPMJHIxv8RCEzIZpXHvbaRF6UTAwS-DVsCPrlQUrFZPFm_-ufADbaE366vP06x48Hv6yhOKct7C5_H3r3qHfsbT70aL-AtZO1Rw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+atorvastatin+on+higher+functions&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=PARALE%2C+G.+P&rft.au=BAHETI%2C+N.+N&rft.au=KULKARNI%2C+P.+M&rft.au=PANCHAL%2C+N.+V&rft.date=2006-04-01&rft.pub=Springer&rft.issn=0031-6970&rft.eissn=1432-1041&rft.volume=62&rft.issue=4&rft.spage=259&rft.epage=265&rft_id=info:doi/10.1007%2Fs00228-005-0073-z&rft.externalDBID=n%2Fa&rft.externalDocID=17712711 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon |